In this case, jurors were asked to evaluate warning-label language, physician testimony, and whether breakage complications were sufficiently tied to product design rather than individual removal technique
In 2024, the five leading GLP-1s generated $46.1 billion, surpassing Keytrudas $29.5 billion by $16.6 billion, and topping the combined $41.2 billion from those two oncological therapies
Compliance Restrictions: No before-and-after visuals, no works or proven claim language, no personal medical advice, no product imagery, no injection or dosing visuals
Follow label instruction and do not exceed recommended daily dose
Januvia Januvia (sitagliptin) is a type 2 diabetes medicine that can help you lower your blood sugar and reach your target goals, when used with diet and exercise